Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colistin + cefoperazone-sulbactam
- Development stage
- Unknown
- Lead developer
- Shaheed Mohtarma Benazir Bhutto Institute of Trauma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Colistin + cefoperazone-sulbactam is an investigational antibiotic combination regimen being evaluated for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii ventilator-associated pneumonia (VAP). The regimen combines colistin, a polymyxin antibiotic that disrupts the bacterial outer membrane by binding to lipopolysaccharides, with cefoperazone-sulbactam. Cefoperazone is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins (PBPs), while sulbactam is a beta-lactamase inhibitor that prevents the enzymatic degradation of cefoperazone and exhibits direct bacteriostatic activity against Acinetobacter species. This combination therapy aims to improve clinical outcomes and survival rates in critically ill patients with severe nosocomial infections where monotherapy may be insufficient.
- Other names
- colistin + cefoperazone + sulbactam
02
Targets
IMM (Inner mitochondrial membrane)PBP (Penicillin-binding protein family)Neuraminidaseβ-lactamase
Beyond the preview
Go deeper on colistin + cefoperazone-sulbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colistin + cefoperazone-sulbactam.